哌罗匹隆对比利培酮治疗精神分裂症的系统评价

发布时间：2018-05-13 16:19

本文选题：哌罗匹隆 + 利培酮　；参考：《中国药房》2017年24期

【摘要】：目的:系统评价哌罗匹隆对比利培酮治疗精神分裂症的疗效与安全性,为临床提供循证参考。方法:计算机检索万方数据库、中文科技期刊数据库、相关期刊论文、中国生物医学文献数据库和PubMed,收集哌罗匹隆(试验组)对比利培酮(对照组)治疗精神分裂症的临床随机对照试验(RCT),提取资料并按照改良后的Jadad评分标准评价纳入研究质量后,采用Rev Man5.0统计软件对各效应指标进行Meta分析。结果:共纳入12项RCT,合计1 050例患者。Meta分析结果显示,两组患者痊愈率比较,差异无统计学意义[OR=0.99,95%CI(0.75,1.30),P=0.93];对照组患者锥体外系反应发生率[OR=0.63,95%CI(0.43,0.92),P=0.02]、泌乳素水平升高发生率[OR=0.23,95%CI(0.14,0.38),P0.001]和体质量增加发生率[OR=0.23,95%CI(0.13,0.39),P0.001]显著高于试验组,差异均有统计学意义。结论:哌罗匹隆与利培酮治疗精神分裂症疗效相当,但哌罗匹隆的安全性优于利培酮。
[Abstract]:Objective: to evaluate the efficacy and safety of risperidone in the treatment of schizophrenia. Methods: Wanfang database, Chinese scientific and technological journal database and full text database of Chinese periodicals were searched by computer. The Chinese biomedical literature database and PubMedwere collected and compared with risperidone (control group) for the treatment of schizophrenia. The data were extracted and evaluated according to the improved Jadad score. Rev Man5.0 statistical software was used to analyze each effect index by Meta. Results: a total of 12 items of RCTs were included. The results of Meta-analysis showed that the recovery rate of the two groups was higher than that of the control group. There was no significant difference in the incidence of extrapyramidal reaction (OR0.6395), prolactin level increase (OR0.2395 CI0.140.38P0.001) and body mass increase (OR0.2395CI0.130.390.39P0.001) in the control group, and there was significant difference between the control group and the control group (P 0.001, P 0.001), and there was no significant difference between the control group and the control group in the incidence of extrapyramidal system reaction (OR0.6395CI0.390.39P0.001), the increase of prolactin level (OR0.23995 CI0.140.38P0.001) and the increase of body mass (0.2395% CI 0.130.390.39P0.001) were significantly higher in the control group than in the control group. Conclusion: piperopyrone and risperidone are effective in the treatment of schizophrenia, but the safety of piperopyrone is superior to risperidone.
【作者单位】：重庆三峡中心医院药学部;川北医学院药学院;西南医科大学药学院;
【基金】：重庆市科技计划项目(No.cstc2015shmszx120073) 重庆市万州区科技计划项目(No.201403055)
【分类号】：R749.3

【相似文献】